相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- GLP-1 receptor agonists, already revolutionizing weight-loss and diabetes treatment, are now being investigated for potential applications in addiction treatment. - Dr. Dhruv Khullar, a physician at Weill Cornell Medical College, expresses optimism about GLP-1s for addiction but cautions against labeling them a "miracle drug." - The TED Radio Hour episode explores whether medication alone can adequately treat a disease as complex as addiction, featuring perspectives from multiple experts. - The discussion highlights the tension between modern pharmacological breakthroughs and the need for comprehensive, multifaceted approaches to addiction care.
- A novel experimental medication targeting brain reward pathways has demonstrated efficacy in helping people with cocaine addiction reduce their drug use, addressing a significant unmet medical need. - Current addiction treatment options exist for alcoholism and opioid use disorder, but no FDA-approved medications are available for stimulant addictions like cocaine, which contribute to approximately half of all overdose deaths in the US. - In a separate small trial, an experimental vaccine designed to prevent cocaine from reaching the brain showed promising results, with vaccinated participants 17% more likely to test negative for cocaine compared to those receiving placebo.
- Veradermics has launched a nationwide Phase 2/3 clinical trial for VDPHL01, a promising non-hormonal oral treatment for androgenetic alopecia, backed by a $75 million funding round. - The investigational drug shows potential for hair growth within two months of treatment, offering an alternative to existing options that often come with hormonal side effects or application challenges. - The multi-center trial aims to enroll 480 male participants across 44 US sites, with preliminary Phase 2 data expected in the coming months.
- A new study demonstrates that long-acting injectable antipsychotics significantly reduced Young Mania Rating Scale scores from 33.8 to 3.0 over one year in adolescents with bipolar mania or schizoaffective disorder. - The treatment enabled 86.2% of adolescent patients to return to school or work, though 28.4% experienced depressive episodes during the follow-up period. - Despite lacking FDA approval for patients under 18, the off-label use of LAI antipsychotics showed notable efficacy and tolerability, with only 12% of participants requiring formulation changes due to adverse events.
- Dr. Lorenzo Galluzzi, a highly cited researcher in cancer immunotherapy, joins Fox Chase Cancer Center as a tenured Associate Professor in the Cancer Signaling and Microenvironment Research Program. - Prior to this appointment, Dr. Galluzzi led research at Weill Cornell Medical College focusing on cancer cell stress responses and immune activation during various cancer therapies. - With over 500 published scientific articles and multiple editorial roles, Dr. Galluzzi brings extensive expertise in tumor immunology and cellular pathology to strengthen Fox Chase's research initiatives.
• Liquid biopsy technology has evolved from detecting circulating tumor cells to identifying specific tumor DNA mutations, enabling more precise treatment targeting in metastatic breast cancer. • Current guidelines recommend cell-free DNA testing to detect actionable mutations like PI3K, AKT, PTEN, HER2, and ESR1, which can be targeted with FDA-approved therapies. • Advanced liquid biopsy techniques now allow early disease detection through MRD testing, particularly beneficial for high-risk patients including triple-negative breast cancer cases and those with significant lymph node involvement.
- A multicenter real-world study of 110 patients treated with teclistamab demonstrated a 62% overall response rate and 51% very good partial response rate, comparable to the pivotal MajesTEC-1 trial despite treating a more heavily pretreated population. - The incidence of severe cytokine release syndrome and neurotoxicity was substantially higher in real-world practice (3.6% and 4.5% respectively) compared to clinical trials (0.6% each), likely due to higher disease burden in routine practice. - Primary intravenous immunoglobulin prophylaxis significantly reduced infection rates by approximately 70%, with patients receiving IVIG showing lower cumulative incidence of grade 3 or higher infections compared to those without prophylaxis. - Analysis of FDA adverse event data across BCMA-targeted therapies revealed teclistamab had the highest rates of life-threatening events and death, with infections being the predominant cause of non-relapse mortality.
